Cargando…

Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study

BACKGROUND: Tenofovir disoproxil (TDF) is a promising salvage therapy for patients with chronic hepatitis B (CHB) who failed regimens of other nucleoside analogues (NAs). In this study, we aimed to investigate the clinical efficacy and safety of TDF monotherapy in Chinese CHB patients with genotypic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jing, Liu, Yue-Ying, Lian, Jiang-Shan, Pan, Li-Fang, Yang, Jian-Le, Huang, Jian-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407037/ https://www.ncbi.nlm.nih.gov/pubmed/28397720 http://dx.doi.org/10.4103/0366-6999.204107

Ejemplares similares

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B
por: Bakhshizadeh, Fatemeh, et al.
Publicado: (2015)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
por: Waters, Laura, et al.
Publicado: (2021)

Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
por: Chang, Young, et al.
Publicado: (2021)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Settings
por: Pan, Calvin Q., et al.
Publicado: (2014)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting
Publicado: (2014)

Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B
por: Razafindrazoto, Chantelli Iamblaudiot, et al.
Publicado: (2022)

Renal Safety of Long-term Tenofovir Disoproxil Fumarate Treatment in Patients With Chronic Hepatitis B
por: Woldemedihn, Gezahegn M, et al.
Publicado: (2023)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?
por: Oh, Hyunwoo, et al.
Publicado: (2017)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
por: Marcellin, Patrick, et al.
Publicado: (2016)

Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment
por: Kozielewicz, Dorota, et al.
Publicado: (2015)

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
por: Buti, Maria, et al.
Publicado: (2014)

Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people living with HIV
por: Hunt, Matthew, et al.
Publicado: (2022)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients
por: Kim, Hyo Jin, et al.
Publicado: (2015)

Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?
por: Kim, Ji Hoon, et al.
Publicado: (2015)

The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B
por: Suoh, Maito, et al.
Publicado: (2020)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
por: Li, Juan, et al.
Publicado: (2021)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
por: Gupta, Samir K., et al.
Publicado: (2019)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study
por: Zheng, Shuqin, et al.
Publicado: (2019)

Long‐term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation
por: Vasudevan, Abhinav, et al.
Publicado: (2018)

Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
por: Chen, Jun-Ze, et al.
Publicado: (2017)

Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results
por: Liang, Xieer, et al.
Publicado: (2019)

Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
por: Pan, Ya-ru, et al.
Publicado: (2023)

Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
por: Aomura, Daiki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vg3sjfa61637fa4oc89rdj6ivc